Pathogenesis and treatment of glucocorticoid-induced osteoporosis

Drugs and Aging

Volumn 12, Issue 6, 1998, Pages 477-484

  Rackoff, Paula J ^a   Rosen, Clifford J ^b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b ST JOSEPH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID;

AGING; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE REMODELING; FALLING; FRACTURE; HIP FRACTURE; HUMAN; HYPOGONADISM; MORBIDITY; MORTALITY; MUSCLE MASS; NUTRITION; NUTRITIONAL STATUS; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; SECONDARY HYPERPARATHYROIDISM; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; WEIGHT REDUCTION;

AGING; BONE DENSITY; CHRONIC DISEASE; CLINICAL TRIALS; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS;

EID: 0031778738     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199812060-00005     Document Type: Article

References (68)

1. Cushing H. Basophil adenomas of the pituitary body and their clinical manifestations. Bull Johns Hopkins Hosp 1932; 50: 137-95.
2. Adler RA, Rosen CJ. Glucocorticoids and osteoporosis. Endocrinol Metab Clin 1994; 23: 641-54
3. Hui SL, Slemenda CW, Johnston CC. Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989; 11: 355-61
4. Kiel DP. The approach to osteoporosis in the elderly patient. In: Rosen CJ, editor. Osteoporosis: diagnostic and therapeutic principles. Totowa (NJ): Humana Press, 1996: 225-39
5. Hui SL, Wiske PS, Norton JA. A prospective study of change in bone mass with age in postmenopausal women. J Chronic Dis 1982; 35: 715-25
6. Cummings SR, Nevitt MC, Browner WS. Risk factors for hip fractures in white women. N Engl J Med 1995; 332: 767-73
7. Greenspan SL, Maitland LA, Myers ER, et al. Femoral bone loss progress with age: a longitudinal study in women over age 65. J Bone Miner Res 1994; 9: 1959-65
8. Ravn P, Hetland ML, Overgaard K, et al. Premenopausal and postmenopausal changes in BMD of the proximal femur measured by dual energy X-ray absorptiometry. J Bone Miner Res 1994; 9: 1975-80
9. Garnero P, Shih WG, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate. J Clin Endocrinol Metab 1994; 79: 1693-700
10. Jones G, Nguyen T, Sambrook P, et al. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology studs. BMJ 1994; 309: 691-5
11. Kessenich CR, Rosen CJ. The pathophysiology of osteoporosis. In: Rosen CJ, editor. Osteoporosis: diagnostic and therapeutic principles. Totowa (NJ): Humana Press, 1996: 47-63
12. Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990; 323: 878-83
13. NIH Consensus Conference: optimal calcium intake. JAMA 1995; 272: 1942-8
14. Doppelt SH, Neer RM, Daly M, et al. Vitamin D deficiency and osteomalacia in patients with hip fractures. Orthop Trans 1983; 7: 512-3
15. Sowers MF, Wallace RB, Hollis BW, et al. Parameters related to 25 OHD levels in a population based study of women. Am J Clin Nutr 1986; 43: 621-8
16. Rosen CJ. The role of insulin-like growth factor in senescence: clues for interventional strategics in the elderly. Endocrinologist 1996; 6: 102-8
17. Hayden JM, Mohan S, Baylink DJ. The insulin like growth factor system and the coupling of formation to resorption. Bone 1994; 17: 93S-8S
18. Rosen CJ, Donahue LR, Hunter SJ. IGFs and bone: the osteoporosis connection. Proc Soc Exp Biol Med 1994; 206: 83-103
19. Rudman D. Growth hormone, body composition and aging. J Am Genatr Soc 1985; 33: 800-7
20. Mohan S, Farley J, Baylink DJ. Age-related changes in IGFBP-4 and IGFBP-5 in human serum and bone: implications for the bone loss of aging. Prog Growth Factor Res 1995; 4: 465-73
21. Rosen CJ, Donahue LR, Hunter SJ, et al. The 24/25 kD IGFBP is increased in elderly women with hip and spine fractures. J Clin Endocrinol Metab 1992; 74: 24-7
22. Rajaram S, Baylink DJ, Mohan S. IGFBPs in serum and other biological fluids: regulation and function. Endocr Rev 1997; 18: 801-32
23. Lukert BP, Kream BE. Clinical and basic aspects of glucocorticoid action in bone. In: Bilezikian JP, Raisz LG, Rodan G, editors. Principles of bone biology. San Diego (CA): Academic Press, 1996: 533-48
24. Canalis E. Effect of glucocorticoids on type 1 collagen synthesis, alkaline phosphatase activity and DNA content in cultured rat calavariae. Endocrinology 1988; 112: 931-5
25. Dempster D. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989; 4: 137-41
26. Delaney AM, Gabbitas BY, Canalis E. Cortisol down regulates osteoblast alpha 1 procollagen mRNA by transcriptional and post transcriptional mechanisms. J Cell Biochem 1995; 57: 488-94
27. McCarthy TL, Centrella M, Canalis E. Cortisol inhibits synthesis of IGF-1 in skeletal cells. Endocrinology 1990; 126: 1569-75
28. Conover CA, Bale LK, Clarkson JT. Regulation of IGFBP-5 messenger RNA expression and protein availability in rat osleoblastic like cells. Endocrinology 1993; 132: 2525-30
29. Godshalk MF, Downs RW. Effect of short term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res 1988; 3: 113-5
30. Morris HA, Need AG, O'Loughlin PD, et al. Malabsorption of calcium in corticosteroid induced osteoporosis. Calcif Tissue Int 1990; 46: 305-8
31. Suzuki Y, Ichikawa Y, Saito E, et al. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients undergoing glucocorticoid therapy. Metabolism 1983; 32: 151-6
32. Delaney AM, Dong Y, Canalis E. Mechanisms of glucocorticoid action in bone cells. J Cell Biochem 1994; 56: 295-302
33. Libanti CR, Baylink DJ. Prevention and treatment of glucocorticoid-induced osteoporosis. Chest 1992; 102: 1426-35
34. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104: 648-51
35. Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodeling. N Engl J Med 1995; 332: 305-11
36. Keene G, Parker M, Pryor G. Mortality and morbidity after hip fractures. BMJ 1993; 307: 1248-50
37. Myers AH, Robinson EG, Van Natta ML, et al. Hip fractures among the elderly: factors associated with in-hospilal mortality. Am J epidemiol 1991; 134: 1128-37
38. US Congress of Technology Assessment. Hip fracture outcomes in people age 50 and over. Washington, DC: US Government Printing Office, 1994: OTA-BP-H 120
39. Riggs BL, Wahner HW, Seeman E, et al. Changes in BMD of the proximal femur and spine with aging. J Clin Invest 1982; 70: 716-23
40. Kanis JA, Delmas P, Burckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 1997; 7: 390-6
41. Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: a worldwide projection. Osteoporos Int 1992; 2: 285-9
42. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture evidence in postmenopausal patients with rheumatoid arthritis: effects of low dose steroids. Ann Rheum Dis 1986; 45: 852-7
43. Michel BA, Block DA, Fries JF. Predictors of fracture in early rheumatoid arthritis. J Rheumatol 1991; 18: 804-8
44. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy, and hip fracture. Ann Rheum Dis 1994; 53: 49-52
45. Saag KJ, Koehnke R, Caldwell JR, et al. Low dose long term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115-23
46. Hanania NA, Chapman KR, Sturtridge WC, et al. Dose related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995; 96 (5 Pt I): 571-9
47. Adinoff AD, Hollister JR. Steroid induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309: 265-8
48. Walsh LJ, Wong CA, Pringle M, et al. Use of oral glucocorticoids in the community and the prevention of secondary osteoporosis. BMJ 1996; 313: 344-6
49. Lems WF, Jahangier ZN, Jacobs JWG, et al. Vertebral fractures with rheumatoid arthritis patients treated with corticosteroids. Clin Exp Rheumatol 1995; 13: 293-7
50. Wolfe AM. The epidemiology of rheumatoid arthritis: a review. Bull Rheum Dis 1968; 19: 518-28
51. Chuang TY, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: a 10 yr epidemiologic and clinical study. Ann Intern Med 1982; 97: 672-7
52. Spector TD, Hall GM, McCloskey EV, et al. Risk of vertebral fracture in women with rheumatoid arthirits. BMJ 1993; 306: 558-68
53. Cooper CC, Wickham C. Rheumatoid arthritis, corticosteroid therapy and hip fracture. In: Christiansen C, Overgaard K, editors. Osteoporosis. Copenhagen: Osteopress, 1990
54. Laan RFJM, Bujjs WCAM, Verbeck ALM, et al. Bone mineral density in patients with recent onset of rheumatoid arthritis: influence of disease activity and functional capacity. Ann Rheum Dis 1993; 52: 21-6
55. Dykman TR, Gluck OS, Murphy WA, et al. Evaluation of factors associated with glucocorticoid induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985; 28: 361-81
56. Hall GM, Spector TD, Griffin JA, et al. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 1993; 36: 1510-6
57. Manning PJ, Evans MR, Reid IR. Normal bone density following cure of Cushing's syndrome. Clin Endocrinol 1992; 36: 229-54
58. Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomized, controlled study. Ann Intern Med 1993 Nov 15: 119 (10): 963-8
59. Adachi JD, Bessen WD, Brown J, et al. Intermittent etidronate to prevent corticosteroid induced osteoporosis. N Engl J Med 1997; 337: 382-7
60. Schnitzer TJ. Alendronate and glucocorticoid induced osteoporosis [abstract 1174]. Arthritis Rheum 1997; 40 (9 Suppl. 2)
61. Sambrook P, Birmingham J, Kelly P. et al. Prevention of corticosteroid induced osteoporosts. N Engl J Med 1993; 328: 1747-52
62. Gallacher SJ, Fenner JAK, Anderson K, et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax 1992; 47: 932-6
63. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid induced bone loss. Br J Rheum 1994; 33: 348-50
64. Diamond T, McGuigan L, Barbagallo S, et al. Cyclical etidronate plus ergocalciferol presents glucocorticoid induced bone loss in postmenopausal women. Am J Med 1995; 98: 459-63
65. Grecu EO, Simmons R, Baylink DJ, et al. Effects of medroxyprogesterone on some parameters of calcium metabolisin in patients with glucocorticoid induced osteoporosis. Bone Miner 1991; 13: 153-61
66. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid induced bone loss. J Bone Miner Res 1992; 7: 1063-9
67. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996 Dec 15; 125: 961-8
68. Healey JH, Paget SA, Williamsrusso P, et al. A randomized placebo-controlled trial of salmon calcitonin for bone loss in glucocorticoid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996; 58: 73-80